20 https://www.biospace.com/articlesrss/ Sun, 25 Sep 2022 09:23:22 -0500 Sun, 25 Sep 2022 09:23:22 -0500 BioSpace ]]>September 24 is World Cancer Research Day, and September is Childhood Cancer Awareness Month. BioSpace spoke with leaders from three companies tackling pediatric glioma. https://www.biospace.com/article/biopharma-makes-progress-against-a-childhood-killer-pediatric-glioma-/ Sat, 24 Sep 2022 09:29:00 -0500 https://www.biospace.com/article/biopharma-makes-progress-against-a-childhood-killer-pediatric-glioma-/ ]]>The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 14-2 against Oncopeptides’ Pepaxto, a drug that has been on the market since 2021 for multiple myeloma under accelerated approval. https://www.biospace.com/article/oncopeptides-ceo-odac-meeting-unexpectedly-contentious-in-cancer-drug-rejection/ Fri, 23 Sep 2022 11:55:00 -0500 https://www.biospace.com/article/oncopeptides-ceo-odac-meeting-unexpectedly-contentious-in-cancer-drug-rejection/ ]]>The FDA will meet Friday to discuss the future of Secura Bio’s Copiktra (duvelisib), which has been approved as a third-line treatment for relapsed or refractory CLL/SLL. https://www.biospace.com/article/fda-advisory-committee-prepares-to-tackle-another-p13k-inhibitor-secura-bio-s-copiktra/ Fri, 23 Sep 2022 00:00:00 -0500 https://www.biospace.com/article/fda-advisory-committee-prepares-to-tackle-another-p13k-inhibitor-secura-bio-s-copiktra/ ]]>One-year data indicates Biogen’s tofersen for SOD1-ALS, slows the decline of the disease through the lowering of SOD1 protein and neurofilament levels. https://www.biospace.com/article/biogen-s-rare-als-drug-slows-progression-at-early-intervention/ Fri, 23 Sep 2022 09:54:00 -0500 https://www.biospace.com/article/biogen-s-rare-als-drug-slows-progression-at-early-intervention/ ]]>​​​​​​​AstraZeneca has decided to drop the hypercholesterolemia candidate AZD8233 through to Phase III, despite meeting its Phase IIb primary efficacy endpoint, its partner Ionis announced Friday. https://www.biospace.com/article/astrazeneca-drops-hypercholesterolemia-aso-candidate-with-ionis-despite-clearing-phase-iib-bar/ Fri, 23 Sep 2022 00:00:00 -0500 https://www.biospace.com/article/astrazeneca-drops-hypercholesterolemia-aso-candidate-with-ionis-despite-clearing-phase-iib-bar/ ]]>Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition. https://www.biospace.com/article/cancer-vaccines-push-toward-viability-with-new-approaches-and-targets/ Fri, 23 Sep 2022 00:00:00 -0500 https://www.biospace.com/article/cancer-vaccines-push-toward-viability-with-new-approaches-and-targets/ ]]>Recently published research into repairing nerve damage caused by injury may also pay off in treating some of the most vexing neurodegenerative diseases like Alzheimer’s.   https://www.biospace.com/article/cell-death-research-could-hold-potential-in-alzheimer-s-other-neurodegenerative-diseases-/ Fri, 23 Sep 2022 12:39:00 -0500 https://www.biospace.com/article/cell-death-research-could-hold-potential-in-alzheimer-s-other-neurodegenerative-diseases-/ ]]>NovoCure announced the launching of a U.S.-based arm to focus on and attempt to grow its glioblastoma (GBM) business and increase its patient population. https://www.biospace.com/article/novocure-to-launch-u-s-cns-cancer-franchise-to-bolster-glioblastoma-portfolio/ Fri, 23 Sep 2022 11:51:00 -0500 https://www.biospace.com/article/novocure-to-launch-u-s-cns-cancer-franchise-to-bolster-glioblastoma-portfolio/ ]]>Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House. https://www.biospace.com/article/patent-proceedings-merck-s-favorable-result-and-amgen-s-supreme-court-case/ Fri, 23 Sep 2022 00:00:00 -0500 https://www.biospace.com/article/patent-proceedings-merck-s-favorable-result-and-amgen-s-supreme-court-case/ ]]>Seven biopharma companies are under new leadership. This week's Movers & Shakers highlights these new chief executive officers who aim to guide their companies into the future. https://www.biospace.com/article/movers-and-shakers-new-ceos-at-seven-biopharma-companies/ Fri, 23 Sep 2022 00:00:00 -0500 https://www.biospace.com/article/movers-and-shakers-new-ceos-at-seven-biopharma-companies/ ]]>This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases.  https://www.biospace.com/article/research-roundup-insights-into-regenerative-medicine-long-covid-immuno-oncology-and-more/ Fri, 23 Sep 2022 11:02:00 -0500 https://www.biospace.com/article/research-roundup-insights-into-regenerative-medicine-long-covid-immuno-oncology-and-more/ ]]>The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements. https://www.biospace.com/article/fda-review-clearpoint-neuro-oncopeptides-iterative-scopes-and-more/ Fri, 23 Sep 2022 00:00:00 -0500 https://www.biospace.com/article/fda-review-clearpoint-neuro-oncopeptides-iterative-scopes-and-more/ ]]>Here are the top six pharmaceutical companies in New Jersey that have job openings now. Find out more about them before applying for a job. https://www.biospace.com/article/top-9-biotech-giants-to-work-for-in-new-jersey-/ Fri, 23 Sep 2022 00:00:00 -0500 https://www.biospace.com/article/top-9-biotech-giants-to-work-for-in-new-jersey-/ Today, the U.S. Food and Drug Administration issued a draft guidance that, when finalized, will provide the agency's perspective on the ethical considerations for including and protecting children in clinical trials. https://www.biospace.com/article/releases/new-fda-draft-guidance-aims-to-protect-children-who-participate-in-clinical-trials/ Fri, 23 Sep 2022 15:46:00 -0500 https://www.biospace.com/article/releases/new-fda-draft-guidance-aims-to-protect-children-who-participate-in-clinical-trials/ The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle. https://www.biospace.com/article/releases/duncan-nri-at-texas-children-s-hospital-accelerates-neurological-research-and-therapies-with-historic-10m-gift-from-the-blue-bird-circle/ Fri, 23 Sep 2022 00:06:00 -0500 https://www.biospace.com/article/releases/duncan-nri-at-texas-children-s-hospital-accelerates-neurological-research-and-therapies-with-historic-10m-gift-from-the-blue-bird-circle/ Evofem Biosciences (OTCPK: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,439,610, which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate).   https://www.biospace.com/article/releases/evofem-announces-issuance-of-u-s-patent-covering-phexxi-composition-of-matter/ Fri, 23 Sep 2022 00:06:00 -0500 https://www.biospace.com/article/releases/evofem-announces-issuance-of-u-s-patent-covering-phexxi-composition-of-matter/ CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation. https://www.biospace.com/article/releases/cytrx-corporation-relaunches-as-ladrx-corporation/ Fri, 23 Sep 2022 00:06:00 -0500 https://www.biospace.com/article/releases/cytrx-corporation-relaunches-as-ladrx-corporation/ Athersys, Inc. announced today that it has entered into amended agreements to extend the exercise period of the warrants that were issued as part of a registered direct offering that closed on August 17, 2022, among other changes, and to issue additional warrants to the same warrant holder, a healthcare-focused U.S. institutional investor. https://www.biospace.com/article/releases/athersys-amends-securities-purchase-agreement-in-connection-with-recent-registered-direct-offering/ Fri, 23 Sep 2022 00:26:00 -0500 https://www.biospace.com/article/releases/athersys-amends-securities-purchase-agreement-in-connection-with-recent-registered-direct-offering/ Caryl Boies professor of cancer research at Cold Spring Harbor Laboratory (CSHL), and his team have found a drug candidate that can prevent lethal lung inflammation in mice by inhibiting a protein called PTP1B. https://www.biospace.com/article/releases/disarming-the-immune-system-s-lethal-lung-response/ Fri, 23 Sep 2022 00:16:00 -0500 https://www.biospace.com/article/releases/disarming-the-immune-system-s-lethal-lung-response/ Alimera Sciences, Inc. announces that it has entered into an agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), acting on the behalf of the DRCR Retina Network. https://www.biospace.com/article/alimera-announces-agreement-with-jaeb-center-for-health-research-on-behalf-of-the-drcr-retina-network/ Fri, 23 Sep 2022 00:00:00 -0500 https://www.biospace.com/article/alimera-announces-agreement-with-jaeb-center-for-health-research-on-behalf-of-the-drcr-retina-network/